These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 28577700)

  • 1. Value for Money in H1N1 Influenza: A Systematic Review of the Cost-Effectiveness of Pandemic Interventions.
    Pasquini-Descomps H; Brender N; Maradan D
    Value Health; 2017 Jun; 20(6):819-827. PubMed ID: 28577700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling control strategies for concurrent epidemics of seasonal and pandemic H1N1 influenza.
    Prosper O; Saucedo O; Thompson D; Torres-Garcia G; Wang X; Castillo-Chavez C
    Math Biosci Eng; 2011 Jan; 8(1):141-70. PubMed ID: 21361405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination strategies for future influenza pandemics: a severity-based cost effectiveness analysis.
    Kelso JK; Halder N; Milne GJ
    BMC Infect Dis; 2013 Feb; 13():81. PubMed ID: 23398722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of 2009 pandemic influenza A(H1N1) vaccination in the United States.
    Prosser LA; Lavelle TA; Fiore AE; Bridges CB; Reed C; Jain S; Dunham KM; Meltzer MI
    PLoS One; 2011; 6(7):e22308. PubMed ID: 21829456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A model-based economic analysis of pre-pandemic influenza vaccination cost-effectiveness.
    Halder N; Kelso JK; Milne GJ
    BMC Infect Dis; 2014 May; 14():266. PubMed ID: 24884470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Community Mitigation Guidelines to Prevent Pandemic Influenza - United States, 2017.
    Qualls N; Levitt A; Kanade N; Wright-Jegede N; Dopson S; Biggerstaff M; Reed C; Uzicanin A;
    MMWR Recomm Rep; 2017 Apr; 66(1):1-34. PubMed ID: 28426646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of vaccination against pandemic influenza in European countries: mathematical modelling analysis.
    Lugnér AK; van Boven M; de Vries R; Postma MJ; Wallinga J
    BMJ; 2012 Jul; 345():e4445. PubMed ID: 22791791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges and lessons learned from implementing a risk-based approach to school advice and closure during the containment phase of the 2009 influenza pandemic in the West Midlands, England.
    Awofisayo A; Ibbotson S; Smith GE; Janmohamed K; Mohamed H; Olowokure B
    Public Health; 2013 Jul; 127(7):637-43. PubMed ID: 23810319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Public health measures at the airport of Hamburg during the early phase of pandemic influenza (H1N1) 2009].
    Schlaich C; Sevenich C; Gau B
    Gesundheitswesen; 2012 Mar; 74(3):145-53. PubMed ID: 21305451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and cost-effectiveness of expanded antiviral prophylaxis and adjuvanted vaccination strategies for an influenza A (H5N1) pandemic.
    Khazeni N; Hutton DW; Garber AM; Owens DK
    Ann Intern Med; 2009 Dec; 151(12):840-53. PubMed ID: 20008760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lessons learnt from pandemic A(H1N1) 2009 influenza vaccination. Highlights of a European workshop in Brussels (22 March 2010).
    Hanquet G; Van Damme P; Brasseur D; De Cuyper X; Gregor S; Holmberg M; Martin R; Molnár Z; Pompa MG; Snacken R; van der Sande M; Van Ranst M; Wirtz A; Neels P
    Vaccine; 2011 Jan; 29(3):370-7. PubMed ID: 21075164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors influencing pandemic influenza vaccination of healthcare workers--a systematic review.
    Prematunge C; Corace K; McCarthy A; Nair RC; Pugsley R; Garber G
    Vaccine; 2012 Jul; 30(32):4733-43. PubMed ID: 22643216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of Ontario's pandemic vaccine program.
    Rolland-Harris E; Tepper M
    Vaccine; 2011 May; 29(22):3829; author reply 3830-1. PubMed ID: 20831912
    [No Abstract]   [Full Text] [Related]  

  • 14. Antiviral treatment for outpatient use during an influenza pandemic: a decision tree model of outcomes averted and cost-effectiveness.
    Venkatesan S; Carias C; Biggerstaff M; Campbell AP; Nguyen-Van-Tam JS; Kahn E; Myles PR; Meltzer MI
    J Public Health (Oxf); 2019 Jun; 41(2):379-390. PubMed ID: 29955851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing households' willingness to pay for an immediate pandemic influenza vaccination programme.
    Asgary A
    Scand J Public Health; 2012 Jul; 40(5):412-7. PubMed ID: 22798286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and cost-effectiveness of vaccination against pandemic influenza (H1N1) 2009.
    Khazeni N; Hutton DW; Garber AM; Hupert N; Owens DK
    Ann Intern Med; 2009 Dec; 151(12):829-39. PubMed ID: 20008759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simulating school closure policies for cost effective pandemic decision making.
    Araz OM; Damien P; Paltiel DA; Burke S; van de Geijn B; Galvani A; Meyers LA
    BMC Public Health; 2012 Jun; 12():449. PubMed ID: 22713694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of vaccine against pandemic influenza A/H1N1 among people with underlying chronic diseases: cohort study, Denmark, 2009-10.
    Emborg HD; Krause TG; Hviid A; Simonsen J; Mølbak K
    BMJ; 2011 Jan; 344():d7901. PubMed ID: 22277542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost effectiveness of pandemic influenza interventions: a pandemic severity based analysis.
    Milne GJ; Halder N; Kelso JK
    PLoS One; 2013; 8(4):e61504. PubMed ID: 23585906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination versus treatment of influenza in working adults: a cost-effectiveness analysis.
    Rothberg MB; Rose DN
    Am J Med; 2005 Jan; 118(1):68-77. PubMed ID: 15639212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.